Literature DB >> 27714809

Physical compatibility of total parenteral nutrition and drugs in Y-site administration to children from neonates to adolescents.

Vigdis Staven1,2, Herra Iqbal2, Siri Wang3, Ingrid Grønlie4,5,6, Ingunn Tho2,7.   

Abstract

OBJECTIVES: Infusion of precipitate or destabilized emulsion can be harmful. The purpose of this study was to obtain Y-site compatibility data on intravenous drugs and total parenteral nutrition (TPN) relevant for children.
METHODS: Two three-in-one TPN admixtures (Olimel N5E and Numeta G16E) used for children of different age groups were tested with ten drugs (ampicillin, ceftazidime, clindamycin, dexamethasone, fluconazole, fosphenytoin, furosemide, metronidazole, ondansetron and paracetamol). Drug : TPN ratios were estimated from a wide range of age and weight classes, and the most extreme mixing ratios (drug > TPN, TPN > drug) in addition to 1 + 1 were chosen. Assessment of potential precipitation was performed by subvisual particle counting, visual examinations and measurements of turbidity and pH. Emulsion stability was investigated by estimation of percentage of droplets above 5 μm (PFAT5), mean droplet diameter and pH measurements. Complimentary theoretical evaluations were performed. KEY
FINDINGS: Ampicillin, fosphenytoin and furosemide precipitated when mixed with TPN. The results for ceftazidime, clindamycin, dexamethasone, fluconazole, metronidazole, ondansetron and paracetamol suggest that they were compatible with either TPN in the tested concentrations. None of the drugs were found to destabilize the emulsions.
CONCLUSION: Three drugs showed clear signs of precipitation when mixed with TPN and these products should not be co-administered in the same infusion line.
© 2016 Royal Pharmaceutical Society.

Entities:  

Keywords:  PFAT5; droplet size; emulsion stability; parallel infusion; precipitation

Mesh:

Substances:

Year:  2016        PMID: 27714809     DOI: 10.1111/jphp.12647

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  7 in total

1.  Physical stability of an all-in-one parenteral nutrition admixture for preterm infants upon mixing with micronutrients and drugs.

Authors:  Vigdis Staven; Siri Wang; Ingrid Grønlie; Ingunn Tho
Journal:  Eur J Hosp Pharm       Date:  2018-07-07

2.  Physical compatibility of alprostadil with selected drugs commonly used in the neonatal intensive care units.

Authors:  Amaya De Basagoiti; Alberto Katsumiti; Silvia Abascal; Alazne Bustinza; Leocadio R López-Giménez; Pilar Pascual; Monike De Miguel; Ainara Campino
Journal:  Eur J Pediatr       Date:  2020-10-31       Impact factor: 3.183

3.  Effect of Lipid Emulsion on Stability of Ampicillin in Total Parenteral Nutrition.

Authors:  Maciej Stawny; Aleksandra Gostyńska; Katarzyna Dettlaff; Anna Jelińska; Eliza Główka; Magdalena Ogrodowczyk
Journal:  Nutrients       Date:  2019-03-06       Impact factor: 5.717

4.  Investigations of Physical Compatibilities of Commonly Used Intravenous Medications with and without Parenteral Nutrition in Pediatric Cardiovascular Intensive Care Unit Patients.

Authors:  Katherine Greenhill; Erin Hornsby; Greg Gorman
Journal:  Pharmaceuticals (Basel)       Date:  2019-05-04

5.  Sodium Valproate Incompatibility with Parenteral Nutrition Admixtures-A Risk to Patient Safety: An In Vitro Evaluation Study.

Authors:  Ludwika Piwowarczyk; Szymon Tomczak; Patryk Antkowiak; Anna Jelińska; Maciej Stawny
Journal:  Pharmaceutics       Date:  2022-02-07       Impact factor: 6.321

6.  The Interactions between Ciprofloxacin and Parenteral Nutrition Admixtures.

Authors:  Aleksandra Gostyńska; Maciej Stawny; Katarzyna Dettlaff; Anna Jelińska
Journal:  Pharmaceutics       Date:  2019-12-27       Impact factor: 6.321

7.  Stability and Compatibility Aspects of Drugs: The Case of Selected Cephalosporins.

Authors:  Szymon Tomczak; Aleksandra Gostyńska; Malwina Nadolna; Karolina Reisner; Marta Orlando; Anna Jelińska; Maciej Stawny
Journal:  Antibiotics (Basel)       Date:  2021-05-09
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.